Confronto

Pasireotid vs. Sincalide

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

396091-73-9

25126-32-3

Peso molecolare

1047.21 g/mol

1143.29 g/mol

Emivita

nessun dato

Sequenza

nessun dato

Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2

Meccanismo d'azione

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Sincalide

Sincalide activates CCK receptors, triggering gallbladder contraction and pancreatic enzyme secretion. This effect is used diagnostically to measure the gallbladder ejection fraction (e.g. in HIDA scintigraphy).

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studio sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Pasireotid	Sincalide
Germania	Su prescrizione	Non chiaro
Stati Uniti	Su prescrizione	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Pasireotid and Sincalide?: Pasireotid is classified as "Ricerca (altro)", while Sincalide is classified as "Ricerca (altro)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Sincalide: Sincalide is the synthetic C-terminal octapeptide of the hormone cholecystokinin (CCK-8). As Kinevac it is FDA-approved to stimulate gallbladder contraction for diagnostic imaging. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pasireotid or Sincalide?: The highest available evidence level is "RCT sull'uomo" for Pasireotid and "Studio sull'uomo" for Sincalide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pasireotid and Sincalide in Germany and the United States?: Germania: Pasireotid — Su prescrizione, Sincalide — Non chiaro. Stati Uniti: Pasireotid — Su prescrizione, Sincalide — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Pasireotid

Sincalide

Germania

Su prescrizione

Non chiaro

Stati Uniti

Su prescrizione

Frequently asked questions

What is the difference between Pasireotid and Sincalide?

Pasireotid is classified as "Ricerca (altro)", while Sincalide is classified as "Ricerca (altro)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Sincalide: Sincalide is the synthetic C-terminal octapeptide of the hormone cholecystokinin (CCK-8). As Kinevac it is FDA-approved to stimulate gallbladder contraction for diagnostic imaging. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pasireotid or Sincalide?

The highest available evidence level is "RCT sull'uomo" for Pasireotid and "Studio sull'uomo" for Sincalide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pasireotid and Sincalide in Germany and the United States?

Germania: Pasireotid — Su prescrizione, Sincalide — Non chiaro. Stati Uniti: Pasireotid — Su prescrizione, Sincalide — Su prescrizione. These are factual summaries with source and review date on the individual pages.